Repurposing Sigma-1 Receptor-Targeting Drugs for Therapeutic Advances in Neurodegenerative Disorders
Neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, and Huntington’s disease, due to their multifaced and complicated nature, remain uncurable and impose substantial financial and human burdens on society. Therefore, developing new innovative therapeutic strategies is vital. In this conte...
Saved in:
| Main Authors: | Kiarash Eskandari, Sara-Maude Bélanger, Véronik Lachance, Saïd Kourrich |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/5/700 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Broad-spectrum antiviral activity of the sigma-1 receptor antagonist PB28 against coronaviruses
by: Gaojie Song, et al.
Published: (2025-08-01) -
The astrocytic sigma-1 receptor constitutes in the fast antidepressant action of hypidone hydrochloride (YL-0919) in rodents
by: Jin-Feng Li, et al.
Published: (2025-03-01) -
NMDA receptors in neurodegenerative diseases: mechanisms and emerging therapeutic strategies
by: Keyi Zhang, et al.
Published: (2025-07-01) -
Análise comparativa da aplicação do programa Seis Sigma em processos de manufatura e serviços Comparative analyses of Six-Sigma program application in manufacturing and services process
by: Luis Ricardo Galvani, et al.
Published: (2013-01-01) -
Features and prospects of implementation of the integrated Lean Six Sigma methodology at the enterprise
by: N. N. Trofimova
Published: (2021-06-01)